GlassScriptPhysician profile
Alexander Karmazin
NPI 1679521470
$8,002.71
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $22.93 · 2021: $180 · 2022: $361 · 2023: $1,552 · 2024: $4,239 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,710 · Travel and Lodging: $1,546 · Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,710.00 |
| Travel and Lodging | $1,546.41 |
| Food and Beverage | $765.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,539.57 | 2023-2025 | |
| Medtronic Minimed, INC. | $1,120.45 | 2019 | |
| Dexcom, INC. | $236.67 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $225.43 | 2022-2023 | Minimed 780g |
| Insulet Corporation | $152.83 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $125.73 | 2019 | |
| Novo Nordisk INC | $125.00 | 2024 | |
| Tolmar, INC. | $114.86 | 2025 | Fensolvi |
| Beta Bionics, INC. | $113.56 | 2023-2024 | Ilet Bionic Pancreas |
| Tandem Diabetes Care, INC. | $100.11 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $92.54 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Zealand Pharma US, INC. | $25.76 | 2021-2022 | |
| Lilly USA, LLC | $17.95 | 2019 | |
| Companion Medical, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Karmazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.